Involving Proteinase Patents (Class 435/23)
  • Patent number: 11209382
    Abstract: A method of calibrating a device for measuring the concentration of creatinine in a sample including one or more enzyme modulators, the method comprising: determining sensitivities of the device for each of two or more calibration solutions, wherein each calibration solution has a different amount of enzyme modulator; determining a degree of modulation for each of the two or more calibration solutions; determining a degree of modulation for a sample to be measured; and calculating the sensitivity of the device for the sample, wherein said calculating comprises modifying the sensitivity of one of the two or more calibration solutions by a function comprising the determined degrees of modulation.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: December 28, 2021
    Assignee: Radiometer Medical APS
    Inventors: Thomas Steen Hansen, Thomas Kjaer, Thomas Pedersen Nygaard
  • Patent number: 11203621
    Abstract: The present invention provides a tool which exhibits excellent properties in the quantification of autophagy activity. A unimolecular FRET probe of the present invention includes an acceptor consisting of a fluorescent protein to be enzymatically degraded inside a lysosome or a vacuole; and a donor having an amino acid sequence having a sequence identity of 95% or more with respect to an amino acid sequence represented by SEQ ID NO: 1.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: December 21, 2021
    Assignee: RIKEN
    Inventors: Atsushi Miyawaki, Hiroyuki Katayama
  • Patent number: 11168145
    Abstract: Aspects of the disclosure provide compositions and methods for treating cancer characterized by surface expression of plectin-1. In some embodiments, the disclosure provides anti-plectin-1 antibodies. In some embodiments, the anti-plectin-1 antibodies are conjugated to a targeted moiety (e.g., a therapeutic moiety or a detectable label).
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: November 9, 2021
    Assignee: ZIELBIO, INC.
    Inventors: Kimberly A. Kelly, Julien Dimastromatteo
  • Patent number: 11162949
    Abstract: A method for rapidly and highly sensitively measuring endotoxin relies on an endotoxin-measuring agent, which includes a factor C derived from Tachypleus tridentatus that does not have His-tag sequence at the C-terminus, a factor B of a horseshoe crab, and a proclotting enzyme of a horseshoe crab. Each of these proteins can be a recombinant protein obtainable by being expressed using a stably expressing cell line of an insect cell as a host.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: November 2, 2021
    Assignee: Seikagaku Corporation
    Inventors: Hikaru Mizumura, Maki Aizawa, Toshio Oda
  • Patent number: 11112412
    Abstract: A kit, composition and method for detection of antibodies to severe acute respiratory syndrome related coronavirus (SARSr-CoV), and for diagnosis of SARSr-CoV infection.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: September 7, 2021
    Assignee: NATIONAL UNIVERSITY OF SINGAPORE
    Inventor: Linfa Wang
  • Patent number: 11104933
    Abstract: The present disclosure relates to compositions, methods and test devices for determining the presence of active leukocyte cells, for example, by using novel LE and/or HNE substrates in an electrochemical assay.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: August 31, 2021
    Assignee: CLEU DIAGNOSTICS, LLC
    Inventors: Andrew Neil Fleischman, Javad Parvizi, Ron H. Bihovsky
  • Patent number: 11092575
    Abstract: Provided are a pretreatment device capable of starting pretreatment in a simple operation, and an analysis system provided with the pretreatment device. A container holding unit 12 holds pretreatment containers into each of which a sample is injected, at a plurality of holding positions. A pretreatment unit sequentially performs pretreatment by using the pretreatment containers held at the holding positions of the container holding unit 12 in a specific order. A controller configured to receives a setting of the holding position of a pretreatment container to be used first among the plurality of holding positions in the case where a series of pretreatments using the plurality of pretreatment containers is started by the pretreatment unit.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: August 17, 2021
    Assignee: SHIMADZU CORPORATION
    Inventors: Nobuhiro Hanafusa, Kazuhiro Suzuki
  • Patent number: 11085041
    Abstract: A method of preparing a library of tagged nucleic acid fragments including contacting a population of cells directly with a lysis reagent having one or more protease to generate a cell lysate; inactivating the protease to generate an inactivated cell lysate, and applying a transposase and a transposon end composition containing a transferred strand to the inactivated cell lysate under conditions wherein the target nucleic acid and the transposon end composition undergo a transposition reaction.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: August 10, 2021
    Assignee: Illumina, Inc.
    Inventors: Fiona Kaper, Gordon Cann
  • Patent number: 11079351
    Abstract: Immobilization zones through which a sample flows before reaching the proteolytic agents and/or active enzyme and associated electrode/s of an electrochemical test sensor may be used to trap or chemically deactivate active enzyme and/or proteolytic agent deactivating agents. Through either trapping or chemical deactivation, the immobilization zones substantially prevent the enzyme deactivating agents from reaching, and thus reducing the activity of the active enzyme or enzymes. Similarly, trapping or chemical deactivation may be used to prevent or substantially reduce the incidence of the proteolytic deactivating agent or agents from reaching the proteolytic agent.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: August 3, 2021
    Inventor: Jim Connolly
  • Patent number: 11031218
    Abstract: A data acquisition method in a mass spectrometer includes a. providing an ion source to generate precursor ions; b. feeding the precursor ions into a first mass analyzer that selects one mass window such that the precursor ions located outside the mass window pass through the first mass analyzer and the precursor ions located within the mass window cannot pass through the first mass analyzer; c. feeding the precursor ions passing through the first mass analyzer into a collision cell for collisional dissociation, to generate product ions; d. feeding the product ions into a second mass analyzer for mass analysis and recording a spectrum; and e. repeating Steps b-d. Each time when Step b is repeatedly performed, the selected mass window does not overlap with all the mass windows previously selected. After all the mass windows in a mass range are selected, the repetition is stopped.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: June 8, 2021
    Assignee: SHIMADZU CORPORATION
    Inventors: Xiaoqiang Zhang, Yunqing Huang, Wenjian Sun
  • Patent number: 10988749
    Abstract: The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a VIM-2 variant with improved properties such as improved protease stability.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: April 27, 2021
    Assignees: DA VOLTERRA, BIOASTER
    Inventors: Jean De Gunzburg, Jean-Denis Docquier
  • Patent number: 10980864
    Abstract: It is disclosed herein that microperoxidases are capable of binding carbon monoxide (CO) with high affinity and displacing CO from hemoglobin, thereby acting as CO scavengers. The present disclosure provides methods of treating carboxyhemoglobinemia (or CO poisoning) in a subject by administering a therapeutically amount of an isolated or recombinant microperoxidase. Methods of removing CO from hemoglobin in blood or tissue by administering a therapeutically amount of an isolated or recombinant microperoxidase are also described. Methods of determining the effectiveness of a microperoxidase for removing CO from hemoglobin are further described.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: April 20, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Mark Thomas Gladwin, Jesus Tejero Bravo
  • Patent number: 10962542
    Abstract: A metabolic biomarker set for use in assessing, screening, and/or diagnosing breast cancer in a mammalian subject includes at least (a) one amino acid selected from glutamine, glutamate and serine, and one lipid, or (b) glutamine and glutamate. Described further, is a metabolic biomarker set for prediction of therapeutic response to breast cancer neoadjuvant chemotherapy; a metabolic biomarker set for assessing biochemical reflection of breast cancer tumor activity; and a metabolic biomarker set for subclassification between intrinsic breast cancer tumor subtypes. Moreover, a method for assessing breast cancer is described, which includes obtaining a biological sample, preferably blood, from a mammalian subject and measuring in the biological sample the amount and/or ratios of metabolites. By employing the specific biomarkers and the method it becomes possible to more properly and reliably assess breast cancer.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: March 30, 2021
    Inventors: Andre Lopes Carvalho, Rene Aloisio Da Costa Vieira, Ismael Dale Cotrim Guerreiro Da Silva, Edson Guimaraes Lo Turco, Therese Koal
  • Patent number: 10936768
    Abstract: Performance of a first generated model can be monitored while the first generated model is deployed for use on live data. The monitoring can include determining a first performance value of the first generated model. Performance of a second generated model can be monitored while the second generated model is deployed for use on live data. The monitoring can include determining a second performance value of the second generated model. A plot including a first axis and a second axis can be rendered. The first axis can include a characterization of a first performance metric and the second axis can include a characterization of a second performance metric. A first graphical object at a first location characterizing the first performance value and a second graphical object at a second location characterizing the second performance value can be rendered. Related apparatus, systems, techniques and articles are also described.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: March 2, 2021
    Assignee: Aible, Inc.
    Inventors: Arijit Sengupta, Jonathan Wray, Grigory Nudelman, Daniel Kane, Geoffrey Grant
  • Patent number: 10916331
    Abstract: Described herein are methods of predicting drug-target interactions and methods of using the information for drug repurposing. The methods described herein combine different descriptors, including, for example, atom pair similarity, shape, topology and chemical signatures, physico-chemical functional descriptors, contact points of the ligand and the target protein, chemical similarity, and docking score.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: February 9, 2021
    Assignee: GEORGETOWN UNIVERSITY
    Inventors: Sivanesan Dakshanamurthy, Stephen W. Byers
  • Patent number: 10858445
    Abstract: The present invention is based on the finding that administration of polypeptides comprising at least one Immunoglobulin single variable domains against vWF to human TTP patients provides a significant decrease in the time to response. The invention provides a polypeptide comprising at least one immunoglobulin single variable domain (ISVD) against von Willebrand Factor (vWF) for use in treating a vWF-related disease in a human in need thereof. The invention further relates to dosage unit forms, kits and medical uses for treating TTP.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: December 8, 2020
    Assignee: Ablynx N.V.
    Inventor: Christian Duby
  • Patent number: 10837965
    Abstract: A method is provided for characterising and/or prognosing prostate cancer in a subject comprising measuring the level of at least one protein from a panel or at least one peptide thereof in a sample from the subject. The method may be used to determine the grade and stage of the prostate cancer. Also disclosed is a method for selecting a treatment for prostate cancer, together with corresponding methods of treatment. Systems and computing devices for performing the methods are also provided.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: November 17, 2020
    Assignee: UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND
    Inventors: Stephen Pennington, Brendan Murphy, William Watson
  • Patent number: 10815500
    Abstract: The present invention relates to Transcription Activator-Like Effector (TALE) derived proteins that allow efficient targeting and/or processing of double stranded nucleic acid sequences. The proteins of the invention are typically chimeric protein monomers composed of a core scaffold comprising Repeat Variable Dipeptide regions (RVDs) having binding specificity to a DNA target sequence, to which is fused a catalytic domain to its N-terminus. This later catalytic domain, which can be a monomer of a nuclease, is placed at this position to possibly interact with another catalytic domain fused to another TAL monomer, such that, when the monomers are binding to their respective target DNA sequences, both catalytic domains form a catalytic entity likely to process DNA in the proximity of these target sequences. This new TAL architecture makes it possible to target only one DNA strand, which is not the case, for instance, with classical TALEN architectures.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: October 27, 2020
    Assignee: Cellectis
    Inventors: Alexandre Juillerat, Philippe Duchateau
  • Patent number: 10788450
    Abstract: A preparation method for an aerolysin nanopore in this disclosure comprises the following steps: (1) pretreatment of an aerolysin; (2) preparation of a lipid bilayer membrane by pulling process; (3) forming of the aerolysin nanopore: the aerolysin nanopore is obtained at a current of 50±5 pA. The aerolysin nanopore prepared in the invention is structurally stable and has a high resolution with the whole internal cavity carried with a positive charge, can be used for detection without modification and is easily operated. Further, the aerolysin nanopore can be applied in DNA sequencing, DNA damage and Micro-RNA detection.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: September 29, 2020
    Assignee: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Yitao Long, Chan Cao, Yongxu Hu
  • Patent number: 10626438
    Abstract: The invention relates to a compound of Formula I: F1—X1-L1-X2—P1—X3-G1??(Formula I).
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: April 21, 2020
    Assignee: The Broad Institute, Inc.
    Inventors: Yan-Ling Zhang, Edward Holson, Florence F. Wagner
  • Patent number: 10620223
    Abstract: Methods are provided for quantifying the fibroblast growth factor receptor 2 protein (FGFR2) directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM)/Multiple Reaction Monitoring (MRM) mass spectrometry. The biological sample may be selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells. A protein sample is prepared from the biological sample and the FGFR2 protein is quantitated in the sample using the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one fragment peptide derived from FGFR2.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: April 14, 2020
    Assignee: Expression Pathology, Inc.
    Inventors: David B. Krizman, Todd Hembrough, Sheeno Thyparambil, Wei-Li Liao
  • Patent number: 10578625
    Abstract: The present invention relates to the field of proteomics and more specifically to a method for analyzing a sample possible containing peptides or modified peptides; in particular useful for biomarker discovery or validation of biomarkers. The method uses isoelectric focusing and mass spectrometry (MS) and enables identification of modified peptides with high resolution and predictability.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: March 3, 2020
    Assignee: GE Healthcare Bio-Sciences AB
    Inventors: Peter Mats Oliviusson, Janne Lehtio, Rui Miguel Mamede-Branca
  • Patent number: 10557857
    Abstract: Disclosed are embodiments of a lateral flow test strip (LFTS) platform which measure osteocalcin (OC) and deoxypyridinoline (Dpd) in saliva to identify early indications of bone loss and minimize bone fracture risk associated with osteoporosis. The OC assay embodiments are based on the experimentally identified optimal markers which exhibit selectivity with very low false positives, and sensitivity relevant to clinical requirements. A prospective clinical study sampling of 20 patients demonstrated excellent correlation of OC in saliva with bone mineral density (BMD). Salivary OC and Dpd levels were validated with a standard commercial ELISA kit against serum (OC) and urine (Dpd).
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: February 11, 2020
    Assignee: Intelligent Optical Systems, Inc.
    Inventors: Manal Beshay, Morgan Hatch
  • Patent number: 10537663
    Abstract: A method for preparing a decellularized tissue-based hydrogel with maximized ability of preserving various tissue-derived proteins, growth factors and cytokines by using a supercritical fluid-organic solvent system through (a) a step of decellularizing a biological tissue by bringing the same to contact with a supercritical fluid and an organic solvent at the same time; (b) a step of washing the decellularized tissue; (c) a step of preparing a decellularized tissue solution by mixing the washed decellularized tissue with one selected from an enzyme solution, an acidic solution and a mixture thereof; (d) a step of titrating the decellularized tissue solution to pH 5.5-7.8 by treating with a basic solution; and (e) a step of allowing the titrated decellularized tissue solution to stand at 30-40° C. and utilizing the same as a tissue engineering material with improved angiogenesis and tissue regeneration abilities.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: January 21, 2020
    Assignee: Korea Institute of Science and Technology
    Inventors: Young Mee Jung, Soo Hyun Kim, Yoo Jin Seo
  • Patent number: 10539566
    Abstract: Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including the detection of levels of variety of biomarkers diagnostic of prostate cancer, including filamin A alone, or in combination with one or more additional biomarkers of prostate cancer, including, PSA, keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, and LY9. Additionally, age can be used as a predictor variable. The invention also provides methods of treating prostate cancer which rely on diagnostic information obtained based on the detection of biomarkers of prostate cancer, including filamin A alone, or in combination with one or more additional biomarkers of prostate cancer, including, PSA, keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, LY9, and/or age. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: January 21, 2020
    Assignee: Berg LLC
    Inventors: Niven Rajin Narain, Vivek K. Vishnudas, Rangaprasad Sarangarajan, Viatcheslav R. Akmaev
  • Patent number: 10508135
    Abstract: Compositions and methods for analyzing protease activity, and especially BoNT/B, BoNT/G, BoNT/D, and/or BoNT/F protease activity, using a cell based assay are provided. Cells express at least two recombinant hybrid proteins each of which includes a fluorophore and a membrane anchoring peptide, and at least one of which includes a BoNT protease recognition and cleavage sequence positioned to release a fluorophore upon cleavage. Analysis is performed by monitoring fluorescence following exposure to a BoNT. The fluorophores are positioned so that no useful FRET occurs between them, permitting fluorescence produced by the non-released fluorophore to be used in data normalization.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: December 17, 2019
    Assignee: BIOMADISON, INC.
    Inventors: Ward C Tucker, Francis Mark Dunning
  • Patent number: 10428366
    Abstract: A method of measuring soluble or insoluble cell or tissue-associated collagenase activity. The substrate includes native collagen fibrils that were stained with COOMASSIE Brilliant Blue R-250. Incubation with collagenase can be observed in real-time by the generation of digested smaller fragments. The degraded blue fragments are obtained by filtration through class fibers, onto which intact collagen fibrils are retained. The filtrate containing the blue collagen fragments is incubated with a detergent in order to extract the blue dye, and the mixture is centrifuged in order to separate the dye in the supernatant from the pellet, which contains de-stained collagen fragments and other insoluble materials contained in the test samples (such as bacterial cells or tissues). The amount of dye extracted is quantified by measuring the amount of dye extracted from these fragments, i.e., the absorbance at 600 nm using a spectrophotometer or an ELISA reader.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: October 1, 2019
    Assignee: University of South Florida
    Inventor: My Lien Dao
  • Patent number: 10415024
    Abstract: The present invention provides polypeptides related to Ralstonia proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: September 17, 2019
    Assignee: POSEIDA THERAPEUTICS, INC.
    Inventors: Eric M. Ostertag, Tseten Yeshi
  • Patent number: 10416171
    Abstract: The present application discloses stability-indicating potency assays for influenza vaccines.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: September 17, 2019
    Assignee: Seqirus UK Limited
    Inventors: Yingxia Wen, Ethan Settembre, Zihao Wang
  • Patent number: 10400263
    Abstract: The present invention concerns rhodamine based fluorescent probes which have use in detecting coagulase-producing bacterial strains. In particular, wherein the bacterial strain is MRSA or MSSA.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: September 3, 2019
    Assignee: Kingston University Higher Education Corporation
    Inventors: Alex Sinclair, Mark Fielder, Adam Le Gresley
  • Patent number: 10392646
    Abstract: The present invention relates to a biosensor capable of measuring the total concentration of one or a plurality of amino acids with the use of a reagentless system comprising an electrode modified by hydrogel that comprises at least one enzyme that oxidizes at least one substrate that is at least one amino acid. In some embodiments, the biosensor comprises a hydrogel comprising alginate. In some embodiments, the biosensor comprises use of a thermophilic bacterial metabolic enzyme immobilized or attached to the hydrogel.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: August 27, 2019
    Assignees: University of Maryland, College Park, Children's National Medical Center, The United States of America, as Represented by The Secretary, Department of Health and Human Services
    Inventors: Omar Bilal Ayyub, Adam Michael Behrens, Peter Kofinas, Marshall Lynn Summar, Juan Manuel Cabrera-Luque, Gary Cunningham, Anton Simeonov, Juan Marugan
  • Patent number: 10351817
    Abstract: This invention provides an Amycolatopsis sp. strain (zhp06), and a method of using the whole cell preparation of the strain for vanillin production. The strain was deposited in China Center for Type Culture Collection on Jul. 26, 2011 with the number of CCTCC NO: M 2011265. Under high concentrations of ferulic acid substrate, the vanillin production by this method can reach more than 10 g/L. The molar conversion rate of ferulic acid is more than 50% and the purity of vanillin is from 80% to 95%. The advantage of this invention includes: repeated use of biocatalyst cells, mild biotransformation condition, low environmental pollution, short production cycle, high product purity and simple purification procedure. It has a great potential for industrial applications.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: July 16, 2019
    Assignee: BGN TECH LLC
    Inventors: Pu Zheng, Hui Li, Xinglin Wang, Jianhai Zhou, Shibiao Chu
  • Patent number: 10328161
    Abstract: The present disclosure features a condensation reaction and a luciferin-unmasking reaction that can be carried out under physiological conditions. In general, the condensation reaction involves reacting a bicyclic reactant with an aminothiol derivative, generating a luciferin or luciferin derivative. A luciferin can provide detectable luminescence. A luciferin derivative can be unmasked to provide detectable luminescence in a luciferin-unmasking reaction. The present disclosure provides bicyclic reactants and aminothiol derivatives suitable for use in the condensation reaction. The condensation and luciferin-unmasking reactions find use in a variety of applications, which are also provided.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: June 25, 2019
    Assignee: The Regents of the University of California
    Inventors: Christopher J. Chang, Carolyn R. Bertozzi, Genevieve C. van de Bittner, Elena A. Dubikovskaya
  • Patent number: 10254280
    Abstract: The invention relates to a channel for trapping particles to be fed to the channel with a fluid. The invention further relates to a flow cell comprising such a channel. The invention also relates to an assembly comprising such a flow cell and a detection means. The invention also relates to a method for trapping particles in such a channel. And finally, the invention relates to a method for analyzing a sample using such an assembly.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: April 9, 2019
    Assignees: Micronit Microtechnologies B.V., Janssen Pharmaceutica NV, NXP B.V.
    Inventors: Marko Theodoor Blom, Monica Brivio, Simone Tanzi, Simon Reuvekamp, Bieke Van Dorst, Lieven Jozef Stuyver, Elfried Van Der Sar
  • Patent number: 10247711
    Abstract: The present invention provides reagents for instrumentation quality control and methods of use thereof. In particular, sets of peptides or other molecules are provided for evaluating the performance of instruments with mass spectrometry (MS) and/or liquid chromatography (LC) functionalities.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: April 2, 2019
    Assignee: Promega Corporation
    Inventors: Joshua Jacques Coon, Michael M. Rosenblatt, Marjeta Urh
  • Patent number: 10246492
    Abstract: Compositions and methods for analyzing intracellular BoNT protease activity, and especially BoNT/B, BoNT/G, BoNT/D, and/or BoNT/F protease activity are provided. Cells express at least two recombinant hybrid proteins each of which includes a fluorophore and a membrane anchoring peptide, and at least one of which includes a BoNT protease recognition and cleavage sequence positioned to release a fluorophore upon cleavage. Analysis is performed by monitoring fluorescence following exposure to a BoNT.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: April 2, 2019
    Assignee: BIOMADISON, INC.
    Inventors: Ward C. Tucker, Francis Mark Dunning
  • Patent number: 10202632
    Abstract: A method for determining the amount of glycated hemoglobin (HbA1c), in which—if required—the erythrocytes in a sample are hemolyzed, the haemoglobin that is then released—if required—is contacted with a proteolytic agent and the glycated hemoglobin degradation products obtained in this way or otherwise are quantified is disclosed. In order to provide such a process and reagents employable therein that has/have the property of sufficient stability of the chemical compounds that are essential to the reaction, the provision of the requisite proteolytic agent in the form of an inactivated protease is proposed, which is then only reactivated in situ.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: February 12, 2019
    Assignee: DiaSys Diagnostic Systems GmbH
    Inventors: Günther Gorka, Yoshifumi Watazu, Erwin Metzmann, Alexandra Lein, Holger Müller, Matthias Grimmler
  • Patent number: 10201896
    Abstract: A processing method is for performing a processing with respect to a processing object in at least one field among biochemistry, biology, and biotechnology. The processing method includes transferring, using at least one arm of a robot configured to perform the processing, a container to a mover with the processing object attached on an inner surface of the container. The processing object is moved, using the mover, to a predetermined position on the inner surface of the container. The processing is performed, using a pipette mounted on the arm, with respect to the processing object at the predetermined position.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: February 12, 2019
    Assignee: KABUSHIKI KAISHA YASKAWA DENKI
    Inventors: Eiji Kihara, Sakae Yamaguchi, Kohei Miyauchi
  • Patent number: 10197576
    Abstract: A method for the identification and localization of proteins or other biomolecules of a histologic tissue section comprises enzymatically digesting the biomolecules of two similar tissue sections while substantially preserving the biomolecule positions in the tissue sections. Next, a mass spectrometric image of the digest products in one of the tissue sections is acquired. Then, the digest products of the other tissue section are extracted and separated and the mass spectra and daughter ion spectra of all the digest products are acquired. A list of all identifiable biomolecules of the tissue section is created by comparing the mass spectra and daughter ion spectra with spectra in biomolecule structure databases or spectral libraries. Finally, the biomolecules in the list are assigned to digest products of the same mass in the mass spectra used to create the mass spectrometric image of the thin tissue section.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: February 5, 2019
    Inventors: Detlev Suckau, Martin Schürenberg, Rainer Paape, Christine Lübbert
  • Patent number: 10191051
    Abstract: Methods and compositions are provided where a transfected cell that produces a hybrid protein with a reporter-containing portion and a botulinum toxin cleavage site is contacted with a botulinum toxin in media having a reduced sodium concentration, thereby increasing the sensitivity. Such media can also be used in combination with elevated cell culture temperatures. Kits that include such media and a botulinum toxin are also described.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: January 29, 2019
    Assignee: BIOMADISON, INC.
    Inventors: Ward C. Tucker, Timothy M. Piazza
  • Patent number: 10119969
    Abstract: The invention provides methods and compositions for the detection and/or quantification of a microbial contaminant, for example, a bacterial endotoxin or a glucan, in a sample. In particular, the invention provides a test cartridge useful in the practice of hemocyte lysate-based assays for the detection and/or quantification of a microbial contaminant in a sample. In addition, the invention provides methods of making and using such cartridges. In addition, the invention provides a rapid, sensitive, multi-step kinetic hemocyte lysate-based assay for the detection and/or quantification of a microbial contaminant in a sample. In addition, the invention provides a glucan-specific lysate that can be used in a variety of assay formats, including, for example, a test cartridge, optionally configured to perform a kinetic assay.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: November 6, 2018
    Assignee: Charles River Laboratories, Inc.
    Inventors: Norman R. Wainwright, Foster T. Jordan
  • Patent number: 10087190
    Abstract: The present disclosure relates to novel lactones such as dihydropyrrole-fused furanones, a novel palladium-catalyzed carbonylation method to make the novel lactones, and method of using the novel lactones as anti-fungal and/or anti-bacteria agents.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: October 2, 2018
    Assignee: PURDUE RESEARCH FOUNDATION
    Inventors: Mingji Dai, Mohamed Seleem, Xianglin Yin
  • Patent number: 10077285
    Abstract: Compositions, methods, articles of manufacture, and kits are provided for storage and delivery of proteins.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: September 18, 2018
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Clayton T. McKee, William Strong
  • Patent number: 10041961
    Abstract: Specific peptides, and derived ionization characteristics of the peptides, from the Insulin Receptor protein (IR), and its isoforms IR-A and IR-B, that are particularly advantageous for quantifying the IR protein, IR-A isoform and/or IR-B isoform, directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and are selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: August 7, 2018
    Assignee: Expression Pathology, Inc.
    Inventors: David B. Krizman, Wei-Li Liao, Sheeno Thyparambil, Todd Hembrough
  • Patent number: 10024797
    Abstract: Herein disclosed are biosensing systems that measure lactose concentration in a solution.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: July 17, 2018
    Assignee: Colorado State University Research Foundation
    Inventors: Kenneth F. Reardon, David S. Dandy, Ryan E. Holcomb
  • Patent number: 10017879
    Abstract: Methods and compositions for generating mixtures of product molecules from an initial chemical array are provided. In the subject methods, a chemical array of surface immobilized first moieties is subjected to cleavage conditions such that a composition of solution phase first moieties is produced. The resultant composition of solution phase first moieties is then contacted with one or more reactants to produce a mixture of product molecules that are different from the first moieties. Also provided are the arrays employed in the subject methods and kits for practicing the subject methods.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: July 10, 2018
    Assignee: AGILENT TECHNOLOGIES, INC.
    Inventors: Mel N. Kronick, Eric M. Leproust
  • Patent number: 9969992
    Abstract: This invention relates to phytases, polynucleotides encoding them, uses of the polynucleotides and polypeptides of the invention, as well as the production and isolation of such polynucleotides and polypeptides. In particular, the invention provides polypeptides having phytase activity under high temperature conditions, and phytases that retain activity after exposure to high temperatures. The invention further provides phytases which have increased gastric lability. The phytases of the invention can be used in foodstuffs to improve the feeding value of phytate rich ingredients. The phytases of the invention can be formulated as foods or feeds or supplements for either to, e.g., aid in the digestion of phytate. The foods or feeds of the invention can be in the form of pellets, liquids, powders and the like.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: May 15, 2018
    Assignee: Syngenta Participations AG
    Inventors: David P. Weiner, Ame I. Solbak, Jr., Ryan McCann
  • Patent number: 9944971
    Abstract: The present invention relates to a method for detecting at least one direct thrombin inhibitor in a sample other than citrate plasma, comprising the step of mixing a sample containing a thrombin inhibitor with a composition containing thrombin under conditions which allow the thrombin to release a detectable substance from a chromogenic substrate.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: April 17, 2018
    Assignee: DOASENSE GmbH
    Inventors: Job Harenberg, Roland Kramer
  • Patent number: 9938561
    Abstract: Provided is a method for diagnosing cancer through a difference with a control group in view of the ratio of a deglycosylated peptide fragment and a non-glycosylated peptide fragment in a protein including an N-linked glycosylation motif. Further provided is a method for diagnosing cancer through the detection of the glycosylation ratio in the protein according to the subject matter enables the diagnosis of cancer with high specificity and sensitivity using at least one existing marker, and can be useful in discovering new markers for diagnosing cancer.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: April 10, 2018
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Youngsoo Kim, Jung-Hwan Yoon, Hyunsoo Kim, Kyunggon Kim, Jonghwa Jin
  • Patent number: 9932622
    Abstract: Methods and devices for determining the healing status of wounds, in particular of chronic wounds are provided. Also provided are kits comprising the diagnostic devices, and methods of wound diagnosis and treatment using the diagnostic devices and methods. A diagnostic apparatus (device) for monitoring wounds that exude a wound fluid and determining whether said wounds would be responsive to treatment with wound therapy such as oxidized cellulose therapy is also provided along with kits comprising the diagnostic apparatus and a wound dressing. Furthermore, methods of prognosing and treating wounds that exude a wound fluid are also provided.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: April 3, 2018
    Assignee: Woundchek Laboratories B.V.
    Inventors: Simon William Bayliff, Breda Mary Cullen, Molly Gibson